Pfizer Inc.
RECOMBINANT VACCINIA VIRUS
Last updated:
Abstract:
The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.
Status:
Application
Type:
Utility
Filling date:
9 Jul 2021
Issue date:
3 Feb 2022